Opioid crisis

DoGE should make ending the opioid crisis its legacy

As President Donald Trump trots the globe shopping for a new Air Force One and takes long-distance phone calls in a quest to end the “bloodbath” in Ukraine, a clear and present – and costly, in more ways than one – danger persists on his own country’s soil. A new, first-of-its-kind study from Avalere Health has found the annual average cost of each opioid use disorder (OUD) case in the US “is approximately $695,000 across all stakeholders analyzed.” Per the report’s executive summary:  The costs to the federal government, state/local government, private businesses, and society are driven by lost productivity for employers ($438 billion), employees ($248 billion), and households ($73 billion).

opioid

Tariff haters don’t live in the Rust Belt

There is a vacant lot at the edge of downtown Philipsburg, Pennsylvania, my hometown. Three years ago, a handsome, sturdy brick factory building stood in that lot, albeit most of the windows were broken, as it had been abandoned for years. After it closed, the building became a favorite hangout for ne’er-do-wells, whose act of arson forced its recent demolition. For decades, though, the clothing factory employed thousands of people and made downtown hum, as workers crowded the restaurants and took care of errands on their lunchbreaks. They – along with the hundreds of people employed by a cigar plant on the outskirts of town – also bought houses and rented properties here and supported locally owned pharmacies, barbers, hardware stores, grocery stores, and the hospital.

Meet the drug manufacturer taking the FDA to task for the opioid crisis

Francis Collins, then head of the powerful National Institutes of Health, got right to the point. In a closed-door meeting with pharmaceutical manufacturer Edwin Thompson, Collins demanded Thompson back off his campaign to drastically cut back the use of prescription opioids for chronic, long-term pain. According to Thompson, Collins admitted healthcare regulators knew there was no science showing opioids were effective for anything but acute, short-term incidents. There was at the same time credible research showing the longer a patient remained on opioids, the greater the risk of addiction. Some studies even suggested long-term use increased pain sensitivity. But on that day in 2019, none of that mattered to Collins.

fda edwin thompson